A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132

Journal of Neurochemistry

Volumn 102, Issue 3, 2007, Pages 913-921

  Zafar, Khan Shoeb ^b   Inayat Hussain, Salmaan H ^a,b   Ross, David ^b  

^a Melaka Institute of Biotechnology   (Malaysia)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Aminochrome; Apoptosis; Dopamine; MG132; Parkinson's disease; Proteasomal inhibition; Quinones

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 2; CASPASE 3; CASPASE 9; DOPAMINE; PROTEASOME; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MEMBRANE POTENTIAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; MESENCEPHALON; METABOLITE; MITOCHONDRIAL MEMBRANE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TIME;

ACETYLCYSTEINE; ANIMALS; APOPTOSIS; CASPASES; CELL LINE, TRANSFORMED; CYSTEINE PROTEINASE INHIBITORS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; LEUPEPTINS; MESENCEPHALON; NERVE DEGENERATION; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA;

RATTUS;

EID: 34447324627     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04637.x     Document Type: Article

References (60)

1. Alam Z. I., Daniel S. E., Lees A. J., Marsden D. C., Jenner P. Halliwell B. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326 1329.
2. Andersen J. K. (2000) What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease? Mech. Ageing Dev. 118, 15 22.
3. Anglade P., Vyas S., Javoy-Agid F., Herrero M. T., Michel P. P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E. C. Agid Y. (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12, 25 31.
4. Antunes F. Cadenas E. (2000) Estimation of H2O2 gradients across biomembranes. FEBS Lett. 475, 121 126.
5. Arriagada C., Dagnino-Subiabre A., Caviedes P., Armero J. M., Caviedes R. Segura-Aguilar J. (2000) Studies of aminochrome toxicity in a mouse derived neuronal cell line: is this toxicity mediated via glutamate transmission? Amino Acids 18, 363 373.
6. Bando Y., Katayama T., Taniguchi M., Ishibashi T., Matsuo N., Ogawa S. Tohyama M. (2005) RA410/Sly1 suppresses MPP+ and 6-hydroxydopamine-induced cell death in SH-SY5Y cells. Neurobiol. Dis. 18, 143 151.
7. Bennett J. P. (1999) Free radicals, oxidative stress and the origin of Parkinson's disease. J. Neurol. Sci. 170, 75 76.
8. Bindoli A., Rigobello M. P. Galzigna L. (1989) Toxicity of aminochromes. Toxicol. Lett. 48, 3 20.
9. Blandini F., Cosentino M., Mangiagalli A. et al. (2004) Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural. Transm. 111, 1017 1030.
10. Bonifati V., Rizzu P., van Baren M. J. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256 259.
11. Bulteau A. L., Lundberg K. C., Humphries K. M., Sadek H. A., Szweda P. A., Friguet B. Szweda L. I. (2001) Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 276, 30057 30063.
12. Chee J. L., Guan X. L., Lee J. Y., Dong B., Leong S. M., Ong E. H., Liou A. K. Lim T. M. (2005) Compensatory caspase activation in MPP+-induced cell death in dopaminergic neurons. Cell Mol. Life Sci. 62, 227 238.
13. Chung K. K., Dawson V. L. Dawson T. M. (2003) New insights into Parkinson's disease. J. Neurol. 250 (Suppl. 3 III15 III24.
14. Chu-Ping M., Slaughter C. A. DeMartino G. N. (1992) Purification and characterization of a protein inhibitor of the 2OS proteasome (macropain). Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology 1119, 330 311.
15. Conway K. A., Rochet J. C., Bieganski R. M. Lansbury Jr. P. T. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346 1349.
16. Dodel R. C., Du Y., Bales K. R., Ling Z. D., Carvey P. M. Paul S. M. (1998) Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons. Neuroscience 86, 701 707.
17. Elkon H., Melamed E. Offen D. (2001) 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol. Neurobiol. 21, 771 781.
18. Fornai F., Lenzi P., Gesi M. et al. (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23, 8955 8966.
19. Galzigna L., De Iuliis A. Zanatta L. (2000) Enzymatic dopamine peroxidation in substantia nigra of human brain. Clin. Chim. Acta 300, 131 138.
20. Graham D. G. (1978) Oxidative pathways for catecholamines in genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633 643.
21. Graham D. G. Klintworth G. K. (1978) Oxidative pathways for catecholamines in genesis of neuromelanin, cytotoxic quinones and superoxide (O2-̇) and hydroxide (OH·) radicals. J. Neuropathol. Exp. Neurol. 37, 619.
22. Hartmann A., Hunot S., Michel P. P. et al. (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl Acad. Sci. USA 97, 2875 2880.
23. Hartmann A., Michel P. P., Troadec J. D., Mouatt-Prigent A., Faucheux B. A., Ruberg M., Agid Y. Hirsch E. C. (2001a) Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J. Neurochem. 76, 1785 1793.
24. Hartmann A., Troadec J. D., Hunot S., Kikly K., Faucheux B. A., Mouatt-Prigent A., Ruberg M., Agid Y. Hirsch E. C. (2001b) Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci. 21, 2247 2255.
25. Huser J. Blatter L. A. (1999) Fluctuations in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. Biochemical Journal 343, 311 317.
26. Ii K., Ito H., Tanaka K. Hirano A. (1997) Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56, 125 131.
27. Jenner P., Dexter D. T., Sian J., Schapira A. H. Marsden C. D. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32 (Suppl. S82 S87.
28. Keller J. N., Huang F. F., Dimayuga E. R. Maragos W. F. (2000a) Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic. Biol. Med. 29, 1037 1042.
29. Keller J. N., Huang F. F., Zhu H., Yu J., Ho Y. S. Kindy T. S. (2000b) Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury. J. Cereb. Blood Flow Metab. 20, 1467 1473.
30. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605 608.
31. Krishnan S., Chi E. Y., Wood S. J. et al. (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 42, 829 837.
32. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106 108.
33. Larsen C. N., Price J. S. Wilkinson K. D. (1996) Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 35, 6735 6744.
34. Leroy E., Boyer R., Auburger G. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451 452.
35. Liu Y., Fallon L., Lashuel H. A., Liu Z. Lansbury Jr. P. T. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209 218.
36. McNaught K. S. Jenner P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191 194.
37. McNaught K. S. Olanow C. W. (2003) Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann. Neurol. 53, S73 S84.
38. McNaught K. S. Olanow C. W. (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol. Aging 27, 530 545.
39. McNaught K. S., Bjorklund L. M., Belizaire R., Isacson O., Jenner P. Olanow C. W. (2002a) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13, 1437 1441.
40. McNaught K. S., Mytilineou C., JnoBaptiste R., Yabut J., Shashidharan P., Jennert P. Olanow C. W. (2002b) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81, 301 306.
41. McNaught K. S., Belizaire R., Isacson O., Jenner P. Olanow C. W. (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179, 38 46.
42. McNaught K. S., Perl D. P., Brownell A. L. Olanow C. W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56, 149 162.
43. Miwa H., Kubo T., Suzuki A., Nishi K. Kondo T. (2005) Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett. 380, 93 98.
44. Mochizuki H., Goto K., Mori H. Mizuno Y. (1996) Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137, 120 123.
45. Moore D. J., Zhang L., Troncoso J., Lee M. K., Hattori N., Mizuno Y., Dawson T. M. Dawson V. L. (2005) Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14, 71 84.
46. Norris E. H., Giasson B. I., Hodara R., Xu S., Trojanowski J. Q., Ischiropoulos H. Lee V. M. Y. (2005) Reversible Inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280, 21212 21219.
47. Ochu E. E., Rothwell N. J. Waters C. M. (1998) Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells. J. Neurochem. 70, 2637 2640.
48. Olanow C. W. Tatton W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123 144.
49. Olanow C. W., Agid Y., Mizuno Y. et al. (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 19, 997 1005.
50. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045 2047.
51. Rock K. L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D. Goldberg A. L. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761 771.
52. Segura-Aguilar J., Metodiewa D. Welch C. J. (1998) Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1381, 1 6.
53. Shen X. M. Dryhurst G. (1998) Iron- and manganese-catalyzed autoxidation of dopamine in the presence of l-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. Chem. Res. Toxicol. 11, 824 837.
54. Sun F., Anantharam V., Zhang D., Latchoumycandane C., Kanthasamy A. Kanthasamy A. G. (2006) Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27, 807 815.
55. Tatton N. A. (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166, 29 43.
56. Zafar K. S., Inayat-Hussain S. H., Siegel D., Bao A., Shieh B. Ross D. (2006a) Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol. Lett. 166, 261 267.
57. Zafar K. S., Siegel D. Ross D. (2006b) A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol. Pharmacol. 70, 1079 1086.
58. Zamzami N., Marchetti P., Castedo M., Zanin C., Vayssiere J. L., Petit P. X. Kroemer G. (1995) Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181, 1661 1672.
59. Zhang Y., Dawson V. L. Dawson T. M. (2000) Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 7, 240 250.
60. Zhivotovsky B. Orrenius S. (2005) Caspase-2 function in response to DNA damage. Biochem. Biophys. Res. Commun. 331, 859 867.